Evidence map›Paper›PMID 31433058›Full record

Trial reportTransactions of the Royal Society of Tropical Medicine and Hygiene2019

A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models.

Michelle A Montgomery, Marcel Ramos, Elizabeth A Kelvin, Arturo Carpio, Alexander Jaramillo, W Allen Hauser, Hongbin Zhang

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Anthelmintics for people with neurocysticercosis.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. CystiHuman: A model of human neurocysticercosis.PLoS computational biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Michelle A MontgomeryDepartment of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, 55 West 125th Street, New York, New York 10027, USA.
Marcel RamosDepartment of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, 55 West 125th Street, New York, New York 10027, USA.
Elizabeth A KelvinDepartment of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, 55 West 125th Street, New York, New York 10027, USA.
Arturo CarpioSchool of Medicine, University of Cuenca, Av 12 de Abril s/n Ciudadela Universitaria, 010201 Cuenca, Ecuador.
Alexander JaramilloInstituto de Diagnóstico por Imágenes, Inés Salcedo 1-99, Cuenca, Ecuador.
W Allen HauserGertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, 630 168th Street, Columbia University, New York, New York 10032, USA.
Hongbin ZhangDepartment of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, 55 West 125th Street, New York, New York 10027, USA.
City University of New York · USColumbia University · US

Funding

Characterizing Factors that Impact the Evolution of Neurocysticercosis Cysts: A Cyst-Level Analysis Using New Statistical Methods for Complex Longitudinal DataR03NS111189 · NINDS · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI KELVIN, ELIZABETH A · 2020 to 2020
$152k
Epidemiology of NeurocysticercosisF31NS051946 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KELVIN, ELIZABETH A · 2005 to 2006
$53k
NINDS NIH HHS F31 NS051946NINDS NIH HHS R03 NS111189
6 · The paper itself

Abstract

backgroundIn neurocysticercosis, the larval form of the pork tapeworm Taenia solium appears to evolve through three phases-active, degenerative and sometimes calcification-before disappearance. The antihelmintic drug, albendazole, has been shown to hasten the resolution of active cysts in neurocysticercosis. Little is known about the time cysts take to progress through each phase, with or without treatment.

methodsWe reconfigured brain imaging data from patient level to cyst level for 117 patients in a randomized clinical trial of albendazole in which images were taken at baseline, 1, 6, 12 and 24 mo. Applying a multistate model, we modelled the hazard of a cyst evolving to subsequent cyst phases before the next imaging (vs no change). We examined the impact of albendazole treatment overall and by patient and cyst characteristics on the hazard.

resultsAlbendazole accelerated the evolution from the active to degenerative phase (HR=2.7, 95% CI 1.3 to 6.5) and from the degenerative phase to disappearance (HR=1.9, 95% CI 1.1 to 3.9). Albendazole's impact was stronger for patients who were male, did not have calcified cysts at baseline and who had multiple cysts in different locations.

conclusionsThis research provides a better understanding of where in the cyst trajectory albendazole has the greatest impact.

Indexed as

AdultAlbendazoleAnimalsAnticestodal AgentsDisease ProgressionFemaleHumansLongitudinal StudiesMaleModels, StatisticalNeurocysticercosisNeuroimagingTaenia soliumTime FactorsAlbendazoleAnticestodal Agentsalbendazolebraincentral nervous systemmultistate modelneurocysticercosisTaenia solium

Identifiers

PMID31433058
PMCPMC6903786
OpenAlexW2969544821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.